Know Cancer

forgot password

A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With CApecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)

Phase 2
18 Years
Open (Enrolling)
Metastatic Pancreatic Adenocarcinoma

Thank you

Trial Information

A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With CApecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)

The study consists of an open-label, safety run-in period which is comprised of 1 or 2
patient cohorts with ~ 9 patients/cohort. This phase of the study will determine the safety
of the capecitabine/ruxolitinib combination in this patient population.

A randomized, double-blind study with two treatment arms will be conducted following the
safety run-in if the results from the first part of the study show that the
capecitabine/ruxolitinib combination was safe and additional patients can be treated. All
patients will receive capecitabine therapy in addition to the ruxolitinib or placebo (Study

Treatment for all patients will consist of repeating 21 day cycles. Capecitabine will be
self-administered for the first 14 days of each cycle and the Study Drug will be
self-administered during the entire 21 day cycle. Treatment cycles will continue as long as
the regimen is tolerated and the patient does not meet any of the discontinuation criteria.
In the event of disease progression, capecitabine therapy will be discontinued but the Study
Drug will continue to administered. Subjects who discontinue treatment with the Study Drug
will continue to be followed to obtain for subsequent treatment regimens and survival.

Inclusion Criteria:

- 18 years of age or older

- Diagnosis of metastatic pancreatic cancer; subjects must have measurable, or
evaluable disease that is histologically confirmed

- Karnofsky performance status of ≥ 60

- Subjects must have failed 1st line gemcitabine treatment for metastatic pancreatic

o An alternate chemotherapeutic agent is an acceptable substitute as 1st line therapy
in the event that the subject was intolerant to, or ineligible to receive

- ≥2 weeks elapsed from the completion of previous chemotherapy, and subjects must have
recovered or be at new stable baseline from any related toxicities

Exclusion Criteria:

- More than 1 prior chemotherapy regimen (not including adjuvant therapy) for
metastatic disease

- Evidence of CNS metastases (unless stable for > 3 months) or history of uncontrolled

- Ongoing radiation therapy or prior radiation therapy administered as a second-line

- Other active malignancy except basal or squamous carcinoma of the skin

- Inability to swallow food or any condition of the upper GI tract that precludes
administration of oral medications

- Inadequate renal, hepatic and bone marrow function demonstrated by clinical
observations and/or laboratory assessments

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Outcome Measure:

Overall survival

Outcome Time Frame:

Randomization through discontinuation or death (approximately over the course of five months)

Safety Issue:


Principal Investigator

Bijoyesh Mookerjee, MD

Investigator Role:

Study Director

Investigator Affiliation:

Incyte Corporation


United States: Food and Drug Administration

Study ID:




Start Date:

August 2011

Completion Date:

December 2013

Related Keywords:

  • Metastatic Pancreatic Adenocarcinoma
  • Metastatic pancreatic cancer
  • Adenocarcinoma
  • Adenocarcinoma, Mucinous
  • Pancreatic Neoplasms



Hinsdale, Illinois  60521
New Britain, Connecticut  06052
Bettendorf, Iowa  52722
Alexandria, Minnesota  56308
Birmingham, Alabama  35294
Fountain Valley, California  92708
Miami, Florida  33176
Columbia, Missouri  65203
Albany, New York  12208
Cleveland, Ohio  44195
Philadelphia, Pennsylvania  19104
Nashville, Tennessee  37203-1632
Austin, Texas  78705
Flint, Michigan  48532
Louisville, Kentucky  40207
McLean, Virginia  22101
Little Rock, Arkansas  72205-7199
Hackensack, New Jersey  07601
Albuquerque, New Mexico  87131-5636
Denver, Colorado  
Boston, Massachusetts  
Charlotte, North Carolina  
Eugene, Oregon  
Milwaukee, Wisconsin  
Indianapolis, Indiana  
Tulsa, Oklahoma